Laboratory Corp Of America Holdings risk profile
44 Elevated one input has moved against it
Measured 1 September 2026 from LH's filed statements. Recomputed nightly.
44 (Elevated), driven by Competitive position at 61, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 16 | Contained | Stable | One-year price volatility — 22.7% |
| Operating pressure | 38 | Normal | Easing | Operating-margin drift — -2.2 percentage points |
| Cash conversion | 26 | Normal | Stable | Capital spending against operating cash — 0.26x |
| Leverage and coverage | 35 | Normal | Stable | Net debt to EBITDA — 2.45x |
| Competitive position | 61 | Stretched | Stable | Operating-margin gap against peers — -3.6 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for Laboratory Corp Of America Holdings